Cargando…
Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma †
SIMPLE SUMMARY: The clinical significance of next-generation sequencing coupled with HRR gene analysis of the benefit of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) treatment in patients with breast cancer is unknown. We analyzed the tumor mutations in homologous recombination (...
Autores principales: | Bartow, Brooke B., Siegal, Gene P., Yalniz, Ceren, Elkhanany, Ahmed M., Huo, Lei, Ding, Qingqing, Sahin, Aysegul A., Guo, Hua, Magi-Galluzzi, Cristina, Harada, Shuko, Huang, Xiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177458/ https://www.ncbi.nlm.nih.gov/pubmed/37173992 http://dx.doi.org/10.3390/cancers15092524 |
Ejemplares similares
-
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
por: Abkevich, V, et al.
Publicado: (2012) -
Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
por: Westphalen, C. Benedikt, et al.
Publicado: (2022) -
Loss of heterozygosity: what is it good for?
por: Ryland, Georgina L., et al.
Publicado: (2015) -
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022) -
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)